Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort.

Researchers compared clinical features of Crohn's disease in 117 patients with orofacial granulomatosis to those without it, and assessed treatment responses to biological and JAK inhibitor therapies. Orofacial granulomatosis was linked to earlier disease onset, more extensive bowel involvement, and modest remission rates across multiple advanced therapies, with higher drug levels associated with better outcomes.

A plain-English summary of the study's own findings — we don't add our own claims or interpretation. Read the full paper for the complete methods and results, and apply your own clinical judgement.